Literature DB >> 18272361

Surveillance of Barrett's oesophagus: is it worthwhile?

M Somerville1, R Garside, M Pitt, K Stein.   

Abstract

OBJECTIVE: To assess the cost-effectiveness of surveillance of Barrett's oesophagus.
DESIGN: Cost-utility model.
SETTING: UK NHS. PATIENTS: One thousand 55-year-old men with Barrett's oesophagus. INTERVENTION: Surveillance programme: endoscopy and biopsy at 3 yearly intervals for non-dysplastic Barrett's oesophagus; low-grade dysplasia yearly; high grade-dysplasia 3 monthly. OUTCOME MEASURES: Incremental cost-effectiveness ratio, expected value of perfect information.
RESULTS: Non-surveillance dominated surveillance (i.e. cost less and conferred more benefit), but there was substantial uncertainty around many of the model inputs. Probabilistic analyses showed that non-surveillance cost less and conferred more benefit in 75% of model runs. Surveillance was cost-effective at usual levels of willingness to pay in 11% of runs. For people with Barrett's oesophagus in England and Wales, a value of pound6.5 million is placed on acquiring perfect information about surveillance of Barrett's oesophagus.
CONCLUSIONS: The PenTAG cost-utility model suggests that surveillance programmes do more harm than good.

Entities:  

Mesh:

Year:  2008        PMID: 18272361     DOI: 10.1016/j.ejca.2008.01.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

Review 1.  Screening and surveillance for Barrett's esophagus: current issues and future directions.

Authors:  Sung E Choi; Chin Hur
Journal:  Curr Opin Gastroenterol       Date:  2012-07       Impact factor: 3.287

2.  Surveillance in Barrett's esophagus: an audit of practice.

Authors:  Adewale Ajumobi; Khaled Bahjri; Christian Jackson; Ronald Griffin
Journal:  Dig Dis Sci       Date:  2009-08-11       Impact factor: 3.199

Review 3.  A systematic and critical review of the evolving methods and applications of value of information in academia and practice.

Authors:  Lotte Steuten; Gijs van de Wetering; Karin Groothuis-Oudshoorn; Valesca Retèl
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

Review 4.  Surveillance of Barrett's oesophagus: do we yet know whether it is worthwhile?

Authors:  Margaret Somerville; Martin Pitt
Journal:  Frontline Gastroenterol       Date:  2010-06-15

5.  Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.

Authors:  Nabil P Rizk; Elliot L Servais; Laura H Tang; Camelia S Sima; Hans Gerdes; Martin Fleisher; Valerie W Rusch; Prasad S Adusumilli
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-01-11       Impact factor: 4.254

6.  Long-term follow-up after anti-reflux surgery in patients with Barrett's esophagus.

Authors:  Joerg Zehetner; Steven R DeMeester; Shahin Ayazi; Jesse L Costales; Florian Augustin; Arzu Oezcelik; John C Lipham; Helen J Sohn; Jeffrey A Hagen; Tom R DeMeester
Journal:  J Gastrointest Surg       Date:  2010-09-08       Impact factor: 3.452

7.  Surveillance in Barrett's esophagus: lessons from behavioral economics.

Authors:  Hashem B El-Serag; Aanand D Naik
Journal:  Gastroenterology       Date:  2009-07-28       Impact factor: 22.682

Review 8.  Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.

Authors:  Chin-Ann J Ong; Pierre Lao-Sirieix; Rebecca C Fitzgerald
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

9.  CYR61 and TAZ Upregulation and Focal Epithelial to Mesenchymal Transition May Be Early Predictors of Barrett's Esophagus Malignant Progression.

Authors:  Joana Cardoso; Marta Mesquita; António Dias Pereira; Mónica Bettencourt-Dias; Paula Chaves; José B Pereira-Leal
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

10.  GERD-Barrett-Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?

Authors:  Romana Illig; Eckhard Klieser; Tobias Kiesslich; Daniel Neureiter
Journal:  Gastroenterol Res Pract       Date:  2013-03-20       Impact factor: 2.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.